# Article information:

Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection - PMC
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150375/>

# Article summary:

1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide with different clinical manifestations.

2. Anti-viral drugs used to treat HIV infection have been repurposed for COVID-19 treatment, including lopinavir/ritonavir and remdesivir.

3. Tenofovir, another nucleotide analog used extensively for HIV treatment and pre-exposure prophylaxis (PrEP), has also been hypothesized as effective in COVID-19.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article provides a comprehensive overview of the current evidence on the efficacy of tenofovir against SARS-CoV-2. The article is well written and provides a clear explanation of the virus’s structure and replication cycle, as well as the potential antiviral therapies that have been proposed for its treatment. The article is based on reliable sources such as peer reviewed journals and scientific studies, which makes it trustworthy and reliable. However, there are some points that could be improved upon in order to make the article more balanced and comprehensive. For example, while the article does mention lopinavir/ritonavir and remdesivir as potential treatments for COVID-19, it does not provide any information on their efficacy or safety profiles. Additionally, while the article mentions that age and comorbidities may explain severity in critical cases, it does not provide any evidence to support this claim or explore possible counterarguments. Furthermore, while the article mentions that people living with HIV might be at particularly high risk for severe progression of COVID-19, it does not provide any evidence to support this claim or explore possible counterarguments either. Finally, while the article mentions that tenofovir has been hypothesized as effective in treating COVID-19, it does not provide any evidence to support this claim or explore possible counterarguments either. In conclusion, while this article is generally well written and based on reliable sources, there are some areas where it could be improved upon in order to make it more balanced and comprehensive.

# Topics for further research:

* Lopinavir/ritonavir efficacy against SARS-CoV-2
* Remdesivir efficacy against SARS-CoV-2
* Age and comorbidities as risk factors for severe COVID-19
* HIV and risk of severe COVID-19
* Tenofovir efficacy against SARS-CoV-2
* Antiviral therapies for SARS-CoV-2

# Report location:

<https://www.fullpicture.app/item/d191b84ff9ac201ecf258367a046fe30>